CenterWatch
  • Search Clinical Trials
  • Clinical Trial Listings
  • Volunteer
  • Learn About Clinical Trials

Cousolre, France

< 2 Miles
Filters

Type

Distance
Age
0
0
Gender
Trial Phase
Sponsor
  • A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

    Phase

    1

    Span

    554 weeks

    Sponsor

    GlaxoSmithKline

    Jerez de la Frontera

    Recruiting

  • Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

    This is a Phase III, randomized, open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig monotherapy versus Pembrolizumab monotherapy for the first-line treatment of participants with locally-advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.

    Phase

    3

    Span

    320 weeks

    Sponsor

    AstraZeneca

    Jerez de la Frontera

    Recruiting

  • Effect of TXA Oral Sol 5% in Patients Treated With DOACs or VKA and Undergoing a Single or Multiple Tooth Extraction

    The purpose of this study is to compare the efficacy, acceptability, and safety of Tranexamic Acid Oral Solution 5% with placebo in the prevention of clinically relevant bleeding events in subjects treated with direct oral anticoagulants or vitamin K antagonists and undergoing a single or multiple tooth extraction. A total of approximately 280 subjects will be randomized in two equal treatment groups (approximately 140 subjects per group) to receive Tranexamic Acid Oral Solution 5% or placebo solution for 7 days. Following screening, eligible subjects can be randomized within 14 days when all eligibility criteria are confirmed. Randomized subjects will undergo tooth extraction(s) and treatment period. The treatment period ends at Visit 5 followed by the follow-up period. The maximal study duration is about 4 weeks.

    Phase

    3

    Span

    60 weeks

    Sponsor

    Hyloris Developments

    Jerez de la Frontera

    Recruiting

  • A Growth Artificial Intelligence Algorithm for leNgth and Weight Study

    Phase

    N/A

    Span

    63 weeks

    Sponsor

    Nutricia Research

    Jerez de la Frontera

    Recruiting

    Healthy Volunteers

  • Treatment of High-risk Non-muscle Invasive Bladder Cancer With IMUNO BGC Moreau RJ as Prophylaxis

    Phase

    2

    Span

    146 weeks

    Sponsor

    Biofabri, S.L

    Jerez de la Frontera

    Recruiting

  • A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma

    Phase

    N/A

    Span

    337 weeks

    Sponsor

    Janssen Pharmaceutica N.V., Belgium

    Jerez de la Frontera

    Recruiting

  • Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma

    The study will enroll participants with moderate to severe uncontrolled asthma who are on low-dose inhaled corticosteroid (ICS) - a long-acting beta-agonist (LABA) or medium-to-high-dose ICS with or without LABA background treatment. The study will be initiated by Lead-in pharmacokinetics (PK) cohort in asthma participants. Participant will be randomised globally, including participants in Lead-in PK cohort (2 arms) and in Part 1 of the study (2 arms). In the Lead-in PK cohort, participants will be randomised to Atuliflapon or placebo (recruitment completed). In Part 1 of the study, participants will be stratified by geographical region, and grouped based on high or low levels of biomarker at screening (Visit 1).

    Phase

    2

    Span

    209 weeks

    Sponsor

    AstraZeneca

    Jerez de la Frontera

    Recruiting

  • Niraparib with BeVAcizumab After Complete CytoreductioN in Patients with OvArian Cancer

    Phase II, randomized, open label, multicenterstudy. Randomization on a 1:1 ratio, stratification performed according to: BRCA status (local assessment) FIGO stage at diagnosis (IIIA versus IIIB/IIIC) Previous hyperthermic intraperitoneal chemotherapy (yes/no).

    Phase

    2

    Span

    422 weeks

    Sponsor

    ARCAGY/ GINECO GROUP

    Jerez de la Frontera

    Recruiting

  • A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI)

    Phase

    N/A

    Span

    134 weeks

    Sponsor

    Janssen Research & Development, LLC

    Jerez de la Frontera

    Recruiting

  • Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

    Phase

    2/3

    Span

    211 weeks

    Sponsor

    Kartos Therapeutics, Inc.

    Jerez de la Frontera

    Recruiting

1-10 of 23
CenterWatch

5000 Centregreen Way, Suite 200
Cary, NC, 27513, USA

Phone: 703.538.7600
Toll Free: 888.838.5578

  • Disclaimer
  • Privacy Policy
  • Term of Use
  • Do Not Sell My Personal Information